Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies

References

• Marshall MJE, Stopforth RJ, Cragg MS. Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? Front Immunol. 2017;8:1245. doi:https://doi.org/10.3389/fimmu.2017.01245.
   PubMed Web of Science ®Google Scholar
• Mossner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity. Blood. 2010;115(22):4393–10. doi:https://doi.org/10.1182/blood-2009-06-225979.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381(9880):1817–26. doi:https://doi.org/10.1016/S0140-6736(13)60313-X.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-Cell Lymphoma. J Clin Oncol. 2017;35(31):3529–37. doi:https://doi.org/10.1200/JCO.2017.73.3402.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Jung S-H, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, et al. A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97(5):758–65. doi:https://doi.org/10.3324/haematol.2011.056531.
   PubMed Web of Science ®Google Scholar
• Evers M, Jak M, Leusen JHW. The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opin Biol Ther. 2018;18(9):973–82. doi:https://doi.org/10.1080/14712598.2018.1508444.
   PubMed Web of Science ®Google Scholar
• Meyer S, Evers M, Jansen JHM, Buijs J, Broek B, Reitsma SE, Moerer P, Amini M, Kretschmer A, Ten Broeke T, et al. New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies. Br J Haematol. 2018;180(6):808–20. doi:https://doi.org/10.1111/bjh.15132.
   PubMed Web of Science ®Google Scholar
• Brandsma AM, Bondza S, Evers M, Koutstaal R, Nederend M, Jansen JHM, Rösner T, Valerius T, Leusen JHW, Ten Broeke T, et al. Potent Fc receptor signaling by IgA leads to superior killing of cancer cells by neutrophils compared to IgG. Front Immunol. 2019;10:704. doi:https://doi.org/10.3389/fimmu.2019.00704.
   PubMed Web of Science ®Google Scholar
• Lohse S, Brunke C, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, van der Winkel JGJ, Leusen JHW, et al. Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. J Biol Chem. 2012;287(30):25139–50. doi:https://doi.org/10.1074/jbc.M112.353060.
   PubMedGoogle Scholar
• Valgardsdottir R, Cattaneo I, Klein C, Introna M, Figliuzzi M, Golay J. Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies. Blood. 2017;129(19):2636–44. doi:https://doi.org/10.1182/blood-2016-08-735605.
   PubMed Web of Science ®Google Scholar
• Engelberts PJ, Voorhorst M, Schuurman J, van Meerten T, Bakker JM, Vink T, Mackus WJM, Breij ECW, Derer S, Valerius T, et al. Type I CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells. J Immunol. 2016;197(12):4829–37. doi:https://doi.org/10.4049/jimmunol.1600811.
   PubMed Web of Science ®Google Scholar
• Evers M, Kruse E, Hamdan F, Lebbink R-J, Leusen JHW. Comment on “Type I CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells”. J Immunol. 2018;200(8):2515–16. doi:https://doi.org/10.4049/jimmunol.1800087.
   PubMedGoogle Scholar
• Meyer S, Nederend M, Jansen JHM, Reiding KR, Jacobino SR, Meeldijk J, Bovenschen N, Wuhrer M, Valerius T, Ubink R, et al. Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting. MAbs. 2016;8(1):87–98. doi:https://doi.org/10.1080/19420862.2015.1106658.
   PubMed Web of Science ®Google Scholar
• Lohse S, Meyer S, Meulenbroek LAPM, Jansen JHM, Nederend M, Kretschmer A, Klausz K, Möginger U, Derer S, Rösner T, et al. An anti-EGFR IgA that displays improved pharmacokinetics and myeloid effector cell engagement in vivo. Cancer Res. 2016;76(2):403–17. doi:https://doi.org/10.1158/0008-5472.CAN-15-1232.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8(3):226–34. doi:https://doi.org/10.1038/nrd2804.
   PubMed Web of Science ®Google Scholar
• Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PWHI, van de Winkel JGJ, Taylor RP. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol. 2011;187(6):3438–47. doi:https://doi.org/10.4049/jimmunol.1101189.
   PubMed Web of Science ®Google Scholar
• Jones JD, Hamilton BJ, Rigby WF. Rituximab mediates loss of CD19 on B cells in the absence of cell death. Arthritis Rheum. 2012;64(10):3111–18. doi:https://doi.org/10.1002/art.34560.
   PubMedGoogle Scholar
• Rossi EA, Goldenberg DM, Michel R, Rossi DL, Wallace DJ, Chang C-H. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood. 2013;122(17):3020–29. doi:https://doi.org/10.1182/blood-2012-12-473744.
   PubMed Web of Science ®Google Scholar
• Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, Franke K, Schornagel K, Verkuijlen P, Janssen H, et al. Neutrophils kill antibody-opsonized cancer cells by trogoptosis. Cell Rep. 2018;23(13):3946–59. e6. doi:https://doi.org/10.1016/j.celrep.2018.05.082.
   PubMed Web of Science ®Google Scholar
• Velmurugan R, Challa DK, Ram S, Ober RJ, Ward ES. Macrophage-mediated trogocytosis leads to death of antibody-opsonized tumor cells. Mol Cancer Ther. 2016;15(8):1879–89. doi:https://doi.org/10.1158/1535-7163.MCT-15-0335.
   PubMedGoogle Scholar
• Treffers LW, Ten Broeke T, Rösner T, Jansen JHM, van Houdt M, Kahle S, Schornagel K, Verkuijlen PJJH, Prins JM, Franke K, et al. IgA-mediated killing of tumor cells by neutrophils is enhanced by CD47-sirpalpha checkpoint inhibition. Cancer Immunol Res. 2020;8(1):120–30. doi:https://doi.org/10.1158/2326-6066.CIR-19-0144.
   PubMed Web of Science ®Google Scholar
• van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017;35(5):544–51. doi:https://doi.org/10.1200/JCO.2016.69.0198.
   PubMed Web of Science ®Google Scholar
• Sandhu S, Mulligan SP. Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia. Haematologica. 2015;100(4):411–14. doi:https://doi.org/10.3324/haematol.2015.124107.
   PubMedGoogle Scholar
• Reiding KR, Lonardi E, Ederveen ALH, Wuhrer M. Ethyl esterification for MALDI-MS analysis of protein glycosylation. Methods Mol Biol. 2016;1394:151–62.
   PubMedGoogle Scholar
• Reiding KR, Blank D, Kuijper DM, Deelder AM, Wuhrer M. High-throughput profiling of protein N-glycosylation by MALDI-TOF-MS employing linkage-specific sialic acid esterification. Anal Chem. 2014;86(12):5784–93. doi:https://doi.org/10.1021/ac500335t.
   PubMed Web of Science ®Google Scholar
• Selman MH, Hemayatkar M, Deelder AM, Wuhrer M. Cotton HILIC SPE microtips for microscale purification and enrichment of glycans and glycopeptides. Anal Chem. 2011;83(7):2492–99. doi:https://doi.org/10.1021/ac1027116.
   PubMed Web of Science ®Google Scholar
• Brandsma AM, Ten Broeke T, Nederend M, Meulenbroek LAPM, van Tetering G, Meyer S, Jansen JHM, Beltran Buitrago MA, Nagelkerke SQ, Nemeth I, et al. Simultaneous targeting of FcgammaRs and FcalphaRI enhances tumor cell killing. Cancer Immunol Res. 2015;3(12):1316–24. doi:https://doi.org/10.1158/2326-6066.CIR-15-0099-T.
   PubMed Web of Science ®Google Scholar
• Boross P, Jansen JHM, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JGJ, Parren PWHI, et al. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica. 2011;96(12):1822–30. doi:https://doi.org/10.3324/haematol.2011.047159.
   PubMed Web of Science ®Google Scholar
• Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol. 2007;179(5):3351–61. doi:https://doi.org/10.4049/jimmunol.179.5.3351.
   PubMed Web of Science ®Google Scholar
• van Diemen FR, Kruse EM, Hooykaas MJG, Bruggeling CE, Schürch AC, van Ham PM, Imhof SM, Nijhuis M, Wiertz EJHJ, Lebbink RJ, et al. CRISPR/Cas9-mediated genome editing of herpesviruses limits productive and latent infections. PLoS Pathog. 2016;12(6):e1005701. doi:https://doi.org/10.1371/journal.ppat.1005701.
   PubMed Web of Science ®Google Scholar